

Toolpoint Newsletter Juli 2017

CSEM

CSEM is awarded the 2017 Hermès Innovation Prize

At the service of industry for over 30 years, CSEM has been rewarded for its technological excellence with a Hermès innovation prize. This award is given each year by the Club de Paris des Directeurs de l'innovation and the European Institute for Creative Strategies and Innovation. (<http://www.csem.ch/Page.aspx?pid=46485>).

NewBornCare: Medically monitoring premature babies with cameras

A contactless and wireless camera system developed by EPFL and CSEM researchers continuously monitors premature babies' vital signs. This system could replace skin sensors, which cause false alarms nearly 90% of the time.

(<http://www.csem.ch/Page.aspx?pid=45889>)

BIOFOS: simple, fast and low-cost detection solution of food contaminations

Within the EU-funded project BIOFOS, CSEM and its partners developed an innovative portable, multi-analytic bio-sensing device to monitor the quality and detect contaminants in olive-oil, nuts and milk. Usually this is performed in specialized laboratories demanding time, effort and money. (<https://ec.europa.eu/digital-single-market/en/news/biofos-simple-fast-and-low-cost-detection-solution-food-contaminations>)

INTEGRA

New Reagent Reservoirs Save Money and Space

<https://www.integra-biosciences.com/en/news/reagent-reservoirs-save-money-space>

INTEGRA Launches New Website

<https://www.integra-biosciences.com/en/news/integra-launches-new-device-responsive-website>

New Low retention pipette tips deliver maximum liquid recovery

<https://www.integra-biosciences.com/en/news/low-retention-pipette-tips-deliver-maximum-liquid-recovery>



Helbling Technik AG

Medical Technologies - a key focus for over two decades

The development of a variety of innovative products for Medical Technology clients, is a key focus for over two decades. Helbling operates innovation centers in Switzerland, Germany and the USA to support clients in developing the next generation medical devices and instruments from idea inception to market launch. A new leaflet summarizes the competencies and experiences regarding medical devices, diagnostics and labsystems, medical software and electronics.

Read more: <https://www.helbling.ch/hol/aktuelles/medical-technologies-a-key-focus-for-over-two-decades>

Schweizer Medizintechnik Industrie Branchenstudie

Die die fünfte Ausgabe der Schweizer Medizintechnik Industrie (SMTI) Branchenstudie liegt vor. Sie ist die umfassendste Industriebefragung und Berichterstattung zur Schweizer Medtech-Branche und wurde durch SWISS MEDTECH (Medical Cluster und FASMED) gemeinsam mit der Helbling Gruppe publiziert.

Weiterlesen: <https://www.helbling.ch/hol/aktuelles/schweizer-medizintechnik-industrie-smti-branchenstudie-2016>

Weitere Neuigkeiten aus der Helbling Technik finden Sie auf unserer Homepage unter «Aktuelles» <https://www.helbling.ch/hol/aktuelles>

HSE, Hombrechtikon Systems Engineering AG

Is a newly founded company that is a spin-off of QIAGEN's Automation Unit and has been operating independently since January 1, 2017. With more than 20 years of experience in life science and diagnostics system automation, the company provides design services for innovative, cutting-edge automated solutions enabling cost-efficient development and decreased time-to-market. In addition to the system engineering competencies including optics, advanced algorithms, and data analytics/statistics, HSE has proven expert knowledge in a wide range of application fields such as NGS, qPCR, PCR, spectrometry and fluorescence-based detection, DNA purification, single cell preparation, Pyrosequencing, and capillary electrophoresis. Please visit www.hseag.com or email Patrick Widler (CCO) patrick.widler@hseag.com



InSphero

InSphero AG, the leading supplier of assay-ready 3D cell culture models for accelerating drug discovery and development, has entered into an agreement with Pfizer Inc. (NYSE:PFE), one of the world's premier biopharmaceutical companies, to develop a novel predictive toxicology assay using InSphero 3D InSight™ Human Liver Microtissues.

<https://insphero.com/images/InSphero-media-release-20170427.pdf>

In the most comprehensive evaluation of 3D spheroid hepatic cultures conducted to date, a publication co-authored by lead toxicologists and drug safety experts at AstraZeneca and Genentech revealed **InSphero 3D InSight™ Human Liver Microtissues** to be a more sensitive and highly specific in vitro model for predicting drug-induced liver injury (DILI) compared to 2D models.

<https://www.insphero.com/company/news/907-comprehensive-study-by-astrazeneca-and-genentech-confirms-superiority-of-insphero-human-liver-microtissues-for-prediction-of-drug-induced-liver-injury>

SuSoS

Swiss Future Technology Forum 2017

Am 1. September 2017 bringen EMPA, SuSoS AG und NTN Innovative Surfaces beim Swiss Future Technology Forum (SFTF) zukunftsorientierte technische Unternehmer zusammen und ermöglichen den Austausch zum Thema "Innovation und Kollaboration". Beides sind Themen die uns alltäglich begegnen und enormes Potential bieten, um als Unternehmen erfolgreich zu sein und zu bleiben.

Anmeldung via: <http://www.sftf.ch/>

ZHAW

BioTech 2017

will provide an interdisciplinary discussion forum for experts in the field of (bio)process analytics and sensor technology. With a strong focus on applications, the conference aims at bringing together scientists and professionals from both industry and academia.

<https://biotech2017.ch/>

